Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab with Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT00913835Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Primary completion
- Oct 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaratumab in ovarian cancer, sponsored by Eli Lilly and Company. Started Jun 2009; status: completed.
02
Drugs
olaratumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00913835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913835.